Asthma Clinical Trial
Official title:
Dietary Interventions in Asthma Treatment:Healthy Eating Better Breathing Asthma Diet Pilot Study
| Verified date | September 2016 |
| Source | Johns Hopkins University |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Institutional Review Board |
| Study type | Interventional |
The study is a randomized, crossover meal-replacement pilot intervention to determine feasibility of a larger scale dietary trial in asthma and gather preliminary evidence for the impact of a healthy diet on asthma outcomes. Participants with doctor-diagnosed asthma were randomized to crossover trial of a 4-week dietary intervention or usual diet with a 4-week washout period. During the dietary intervention, all meals and snacks were provided by the study.
| Status | Completed |
| Enrollment | 19 |
| Est. completion date | February 2013 |
| Est. primary completion date | February 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 50 Years |
| Eligibility |
Inclusion Criteria: - ages 18-50, self-reported physician diagnosis and treatment for asthma within the 12 months prior to enrollment, stable asthma defined as no asthma exacerbation (emergency department visit, systemic steroid treatment, or urgent care visit) or respiratory infection in the 4 weeks prior to enrollment. Exclusion Criteria: - active smokers,pregnant or breastfeeding, using systemic corticosteroids or warfarin, had another major pulmonary diagnosis or significant systemic illness, reported excessive alcohol consumption (over 14 drinks per week or six or more drinks on one or more occasions per week), reported food allergy, or weighed over 350 pounds or changed weight by over ten pounds in the two months prior to screening |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Johns Hopkins University |
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Feasibility as assessed by the number of participant drop outs | Feasibility will be assessed by the number of drop outs. | Change from baseline and 4 weeks | No |
| Primary | Adherence using 24 hour diet recall | Adherence to the dietary intervention will be assessed using self-report of dietary intake via 24 hour dietary recall. | Change from baseline to 4 weeks | No |
| Primary | Adherence assessed by serum carotenoids | Serum carotenoids will be measured at baseline and at 4 weeks. An increase in serum carotenoids is expected with adherence to the dietary intervention. | Change from baseline to 4 weeks | No |
| Secondary | FEV1 | Spirometry will be measured according to the American Thoracic Society standards. The forced expiratory volume in one second (FEV1) will be assessed and compared between baseline and 4 weeks after the dietary intervention | Difference between baseline and 4 weeks | No |
| Secondary | FEV1 | Spirometry will be measured according to the American Thoracic Society standards. The forced expiratory volume in one second (FEV1) will be assessed and compared between baseline and 2 weeks after the dietary intervention | Difference between baseline and 2 weeks | No |
| Secondary | FVC | Spirometry will be measured according to the American Thoracic Society standards. The forced vital capacity (FVC) will be assessed and compared between baseline and 4 weeks after the dietary intervention | Difference between baseline and 2 weeks | No |
| Secondary | FVC | Spirometry will be measured according to the American Thoracic Society standards. The forced vital capacity (FVC) will be assessed and compared between baseline and 4 weeks after the dietary intervention | Difference between baseline and 4 weeks | No |
| Secondary | FEV1/FVC ratio | Spirometry will be measured according to the American Thoracic Society standards. The forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio will be assessed and compared between baseline and 4 weeks after the dietary intervention | Difference between baseline and 4 weeks | No |
| Secondary | FEV1/FVC ratio | Spirometry will be measured according to the American Thoracic Society standards. The forced expiratory volume in one second (FEV1)/forced vital capacity (FVC) ratio will be assessed and compared between baseline and 2 weeks after the dietary intervention | Difference between baseline and 2 weeks | No |
| Secondary | Asthma status | Asthma Control Test (ACT, range 5-25, higher score denoting better asthma control). The change in score between baseline and week 4 will be assessed. | Difference between baseline and 4 weeks | No |
| Secondary | Asthma status | Asthma Control Test (ACT, range 5-25, higher score denoting better asthma control). The change in score between baseline and week 2 will be assessed. | Difference between baseline and 2 weeks | No |
| Secondary | Asthma Symptom Utility Index | Asthma Symptom Utility Index (ASUI, range 0-1, higher score denoting fewer symptoms) will be measured and the difference between week 4 and week 0 will be assessed. | Difference between baseline and 4 weeks | No |
| Secondary | Asthma Symptom Utility Index | Asthma Symptom Utility Index (ASUI, range 0-1, higher score denoting fewer symptoms) will be measured and the difference between week 2 and week 0 (baseline) will be assessed. | Difference between baseline and 2 weeks | No |
| Secondary | Asthma Quality of Life Questionnaire (AQLQ) | Asthma Quality of Life Questionnaire (AQLQ) is a 32 item questionnaire and each question uses a 7-point Likert scale (7 = not impaired at all; - 1 = severely impaired). Scores between week 0 (baseline) and week 4 will be assessed. | Difference between baseline and 4 weeks | No |
| Secondary | Asthma Quality of Life Questionnaire (AQLQ) | Asthma Quality of Life Questionnaire (AQLQ) is a 32 item questionnaire and each question uses a 7-point Likert scale (7 = not impaired at all - 1 = severely impaired). Scores between week 0 (baseline) and week 2 will be assessed. | Difference between baseline and 2 weeks | No |
| Secondary | Exhaled nitric oxide | Exhaled nitric oxide is an indicator of airway inflammation and will be measured according to American Thoracic Society standards at baseline and 4 weeks. | Difference between baseline and 4 weeks | No |
| Secondary | Exhaled nitric oxide | Exhaled nitric oxide is an indicator of airway inflammation and will be measured according to American Thoracic Society standards at baseline and 2 weeks. | Difference between baseline and 2 weeks | No |
| Secondary | Adherence assessed by serum carotenoids | Serum carotenoids will be measured at baseline and at 4 weeks. An increase in serum carotenoids is expected with adherence to the dietary intervention. | Difference between baseline and 2 weeks | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|